You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Bruton tyrosine kinase

Showing 1 - 25 of 3,917
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Malignancies Undergoing Treatment With Bruton Tyrosine

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Non-Interventional Study
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Nov 22, 2023

Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest Trial in New Hyde Park (Medtronic

Recruiting
  • Atrial Fibrillation
  • +4 more
  • Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
  • New Hyde Park, New York
    Northwell (Northshore University/Long Island Jewish Hospitals)
Dec 1, 2022

r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase

Not yet recruiting
  • B-cell Lymphoma
  • Beijing, Beijing, China
    Deparment of Hematology, Peking University People's Hospital
Aug 9, 2022

Multiple Sclerosis Trial run by the National Institute of Neurological Disorders and Stroke (NINDS) (tolebrutinib 60mg,

Active, not recruiting
  • Multiple Sclerosis
  • tolebrutinib 60mg
  • tolebrutinib 120mg
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial (BGB-11417)

Not yet recruiting
  • Leukemia
  • +4 more
  • (no location specified)
Jul 27, 2022

CNS Lymphoma Trial in Petah Tikva (Imbruvica)

Recruiting
  • Central Nervous System Lymphoma
  • Petah Tikva, Israel
    Hematology Institute
May 9, 2022

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
Jan 20, 2023

Waldenstrom Macroglobulinemia Trial (Zanubrutinib)

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • (no location specified)
Nov 28, 2022

Hepatitis, Safety and Tolerability Trial run by the NHLBI (HEPLISAV-B)

Completed
Has Results
  • Hepatitis
  • Safety and Tolerability
  • HEPLISAV-B
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 13, 2022

Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 22, 2022

Adult Chronic Lymphocytic Leukemia Receiving Oral Venetoclax

Recruiting
  • Chronic Lymphocytic Leukemia
    • London, London, City Of, United Kingdom
    • +9 more
    Jan 13, 2023

    REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy

    Not yet recruiting
    • CLL, Relapsed
    • +3 more
      • Clermont-Ferrand, France
      • +7 more
      Nov 16, 2022

      Neuromyelitis Optica Trial in Beijing (zanubrutinib)

      Recruiting
      • Neuromyelitis Optica
      • Beijing, Beijing, China
        XuanWu Hospital
      May 15, 2022

      Immune Thrombocytopenia, Bruton Tyrosine Kinase Trial in Beijing (Zanubrutinib)

      Recruiting
      • Immune Thrombocytopenia
      • Bruton Tyrosine Kinase
      • Beijing, Beijing, China
        Peking University Insititute of Hematology, Peking University Pe
      Mar 6, 2022

      Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

      Not yet recruiting
      • Recurrent Chronic Lymphocytic Leukemia
      • +3 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Jan 10, 2023

      Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI

      Active, not recruiting
      Has Results
      • Safety and Tolerability
      • +3 more
      • Zoster Vaccine Recombinant, Adjuvanted
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 10, 2022

      Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)

      Active, not recruiting
      • Waldenstrom Macroglobulinemia
      • Changchun, China
      • +5 more
      Jan 27, 2023

      MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

      Active, not recruiting
      • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
      • +9 more
      • BTK inhibitor PCI-32765
      • +5 more
      • Columbus, Ohio
        Ohio State University Medical Center
      Jun 27, 2022

      Food Allergy, Food Allergy Peanut Trial in Baltimore (Acalabrutinib)

      Recruiting
      • Food Allergy
      • Food Allergy Peanut
      • Baltimore, Maryland
        Johns Hopkins Bayview Medical Center
      Dec 30, 2021

      Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

      Withdrawn
      • Recurrent Follicular Lymphoma
      • +8 more
      • (no location specified)
      Jun 2, 2022

      Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)

      Recruiting
      • Chronic Lymphocytic Leukemia
      • Small Lymphocytic Lymphoma
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Nov 2, 2022

      Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

      Recruiting
      • Blastoid Variant Mantle Cell Lymphoma
      • +8 more
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 5, 2022

      Waldenstrom Macroglobulinemia Trial in Japan (Ibrutinib, Rituximab)

      Active, not recruiting
      Has Results
      • Waldenstrom Macroglobulinemia
      • Chiba, Japan
      • +8 more
      Jan 27, 2023

      Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

      Recruiting
      • Chronic Lymphocytic Leukemia
      • +2 more
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Jan 4, 2023

      Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)

      Recruiting
      • Chronic Lymphocytic Leukemia
      • Small Lymphocytic Lymphoma
      • Houston, Texas
        M D Anderson Cancer Center
      Jul 14, 2022